Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia

World Journal of Urology

Volumn 30, Issue 3, 2012, Pages 419-426

  Fourcade, Richard Olivier ^a   Lacoin, François ^b   Rouprêt, Morgan ^c   Slama, Alain ^d   Le Fur, Camille ^d   Michel, Emilie ^e   Sitbon, Axel ^e   Cotté, François Emery ^d  

^a Centre Hospitalier Auxerre   (France)

^b General Practice ^*  (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d GLAXOSMITHKLINE   (France)

^e Cegedim Strategic Data ^*  (France)

Author keywords

5 alpha reductase inhibitor; Alpha blocker; Benign prostatic hyperplasia; Combination therapy; Lower urinary tract symptoms; Phytotherapy; Quality of life; Utility

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; STEROID 5ALPHA REDUCTASE INHIBITOR;

AGED; ARTICLE; CROSS-SECTIONAL STUDY; DRUG COMBINATION; FRANCE; GENERAL PRACTICE; GENERAL PRACTITIONER; HUMAN; LOWER URINARY TRACT SYMPTOM; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHYTOTHERAPY; PROSTATE HYPERTROPHY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FRANCE; GENERAL PRACTICE; GENERAL PRACTITIONERS; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHYTOTHERAPY; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84861609254     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-011-0756-2     Document Type: Article

References (28)

1. Robert G, Descazeaud A, Azzouzi R, Saussine C, Haillot O, Dumonceau O et al (2010) Impact of lower urinary tract symptoms on discomfort in men aged between 50 and 80 years. Urol Int 84(4): 424-429.
2. Desgrandchamps F, de la Taille A, Azzouzi A, Fourmarier M, Haillot O, Lukacs B et al (2006) Management of non-complicated BPH: proposition of a renewed decision tree. World J Urol 24(4): 367-370.
3. McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, Foster HE Jr, Gonzalez CM, Kaplan SA, Penson DF, Ulchaker JC, Wei JT (2011) Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 185(5): 1793-1803.
4. Fourcade RO, Théret N, Taïeb C (2008) Profile and management of patients treated for the first time for lower urinary tract symptoms/benign prostatic hyperplasia in four European countries. BJU Int 101(9): 1111-1118.
5. Barry MJ, Fowler FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK (1995) Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement committee of the american urological association. Med Care 33(4 Suppl): 145-155.
6. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ (2004) EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46(5): 547-554.
7. Fine SR, Ginsberg P (2008) Alpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: issues and potential complications. J Am Osteopath Assoc 108(7): 333-337.
8. Hong SJ, Rayford W, Valiquette L, Emberton M (2005) The importance of patient perception in the clinical assessment of benign prostatic hyperplasia and its management. BJU Int 95(1): 15-19.
9. Tanguay S, Awde M, Brock G, Casey R, Kozak J, Lee J et al (2009) Diagnosis and management of benign prostatic hyperplasia in primary care. Can Urol Assoc J 3(3 Suppl): 92-100.
10. Jouanneau L, Aout M, Hodé C, Moysan V, Fournier A, Merlière Y, Vicault E, Lukacs B (2008) Observa-Pur. Analyse des prescriptions médicamenteuses pour HBP en France en 2004. Prog Urol 18: 707.
11. Cotté FE, Fardellone P, Mercier F, Gaudin AF, Roux C (2010) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21(1): 145-155.
12. Barry MJ, Fowler FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK et al (1992) The American urological association symptom index for benign prostatic hyperplasia. The measurement committee of the American urological association. J Urol 148(5): 1549-1557.
13. Chevalier J, De Pourville G et al. (2009) Valuing EQ-5D using time trade-off in France. In: Proceedings of the 26th plenary meeting of the EuroQol Group. Paris, France.
14. Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I et al (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 57(1): 123-131.
15. Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Morrill B et al (2008) The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 179(2): 616-621.
16. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349(25): 2387-2398.
17. Black L, Grove A, Morrill B (2009) The psychometric validation of a US English satisfaction measure for patients with benign prostatic hyperplasia and lower urinary tract symptoms. Health Qual Life Outcomes 7: 55.
18. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJMCH (2004) EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46(5): 547-554.
19. Nickel JC, Méndez-Probst CE, Whelan TF, Paterson RF, Razvi H (2010) 2010 Update: guidelines for the management of benign prostatic hyperplasia. Can Urol Assoc J 4(5): 310-316.
20. Fourcade RO, Picot M, Gaudin AF, Texier N, Slama A (2007) Factors determining treatment strategies for patients with benign prostatic hyperplasia. The DUO study. Press Med 36(5 Suppl): 755-763.
21. Nickel JC (2006) The economics of medical therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. Curr Urol Rep 7(4): 282-287.
22. Engstrom G, Henningsohn L, Walker-Engstrom ML, Leppert J (2006) Impact on quality of life of different lower urinary tract symptoms in men measured by means of the SF 36 questionnaire. Scand J Urol Nephrol 40(6): 485-494.
23. Engström G, Walker-Engström ML, Henningsohn L, Lööf L, Leppert J (2004) Prevalence of distress and symptom severity from the lower urinary tract in men: a population-based study with the DAN-PSS questionnaire. Fam Pract 21(6): 617-622.
24. Engström G, Henningsohn L, Steineck G, Leppert J (2005) Self-assessed health, sadness and happiness in relation to the total burden of symptoms from the lower urinary tract. BJU Int 95(6): 810-815.
25. Coyne KS, Wein AJ, Tubaro A, Sexton CC, Thompson CL, Kopp ZS, Aiyer LP (2009) The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int 103(Suppl 3): 4-11.
26. Rutten-van Mölken MPMH, Oostenbrink JB, Tashkin DP, Burkhart D, Monz BU (2006) Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest 130(4): 1117-1128.
27. Vexiau P, Mavros P, Krishnarajah G, Lyu R, Yin D (2008) Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. Diabetes Obes Metab 10(1 Suppl): 16-24.
28. Monz B, Pons ME, Hampel C, Hunskaar S, Quail D, Samsioe G et al (2005) Patient-reported impact of urinary incontinence-results from treatment seeking women in 14 European countries. Maturitas 52(2 Suppl): 24-34.